Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a Topoisomerase I inhibitor presented as a sterile injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Kabi is a Topoisomerase I inhibitor used primarily in colorectal cancer therapy.

Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based chemotherapy. Small cell lung cancer (second‑line): provides tumor control after failure of first‑line regimens. Advanced pancreatic cancer (clinical trials): investigated as part of combination protocols to enhance response rates.

Irinotecan Kabi is associated with a range of adverse reactions.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during and after infusion. - Diarrhea: may be severe and require antidiarrheal therapy. - Neutropenia: reduced white‑blood‑cell count increasing infection risk. - Fatigue: generalised tiredness often reported by patients.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count, a medical emergency. - Severe colitis: intense inflammation of the colon leading to dehydration. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis during infusion. - Hepatic toxicity: elevated liver enzymes indicating liver injury. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

Prior to initiating Irinotecan therapy, several safety considerations are recommended.

Dose adjustment in hepatic impairment: reduce dose based on liver function tests. Monitor blood counts regularly: weekly complete blood count during treatment cycles. Assess renal function: evaluate creatinine clearance before each dose. Avoid in patients with known hypersensitivity to irinotecan or formulation excipients. Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): markedly reduce irinotecan exposure. - UGT1A1 inhibitors (e.g., atazanavir): increase SN‑38 levels and toxicity. - Concurrent myelosuppressive agents: amplify risk of severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may worsen constipation associated with irinotecan. - Warfarin: monitor INR as irinotecan can affect anticoagulant control. - Fluoropyrimidines (e.g., 5‑FU): increase gastrointestinal toxicity when used together.